Vinblastine sulfate

Catalog No.S4505 Batch:S450502

Print

Technical Data

Formula

C46H58N4O9.H2SO4
Molecular Weight 909.05 CAS No. 143-67-9
Solubility (25°C)* In vitro DMSO 100 mg/mL (110.0 mM)
Water 50 mg/mL (55.0 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. Vinblastine sulfate induces autophagy and apoptosis.
Targets
nAChR [1]
(Adrenal Chromaffin Cells)
8.9 μM
In vitro The average terminal half-lives of Vinblastine is 14.3 h. When incubated in freshly isolated rat hepatocytes, VLB penetrates rapidly and intensely into the cells, probably through a passive diffusion mechanism followed by tight cellular binding[3]. Vinblastine inhibits the angiogenic response induced by adrenomedullin and is also positive for mitotic slippage, causing micronuclei in mononucleate cells with cytokinesis block[4]. vinblastine gives significant increase in micronucleated mononucleated cells at concentrations that produced approximately 50% cell death and cytostasis or less as calculated using RPD, RICC and RCC[2].
In vivo Vinblastine is a widely used anticancer drug with undesired side effects [6]. A combination of VBL and RAP at very low doses against human HCC gets a satisfactory antiangiogenic effect in vivo[4]. The clinically relevant dose of vinblastine inhibits palmitoylation of tubulin in vivo in CEM cells (effect on depalmitoylation of tubulin)[5].

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    Chinese hamster ovary (CHO) cells

  • Concentrations

    1% (v/v) (dissolved in DMSO)

  • Incubation Time

    3h

  • Method

    Six-well treatment plates are set up that contained 5 × 104 cells/mL in each well, suspended in 3 mL culture medium, and these are treated with vinblastine for 3 h followed by 21 h growth.

Selleck's Vinblastine sulfate has been cited by 38 publications

Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response [ J Immunother Cancer, 2023, 11(8)e007253] PubMed: 37652576
Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response [ J Immunother Cancer, 2023, 10.1136/jitc-2023-007253] PubMed: 37652576
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer [ Cell Rep, 2023, 42(4):112324] PubMed: 37000626
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells [ J Neurooncol, 2023, 164(3):617-632] PubMed: 37783879
Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells [ J Neurooncol, 2023, 164(3):617-632] PubMed: 37783879
The FAP α -activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway [ Acta Pharm Sin B, 2022, 12(3):1288-1304] PubMed: 35530139
Quantitative reactive cysteinome profiling reveals a functional link between ferroptosis and proteasome-mediated degradation [ Cell Death Differ, 2022, 10.1038/s41418-022-01050-8] PubMed: 35974250
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine [ Front Endocrinol -Lausanne), 2022, 13:1106175] PubMed: 36601001
CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine [ Front Endocrinol (Lausanne), 2022, 13:1106175] PubMed: 36601001
Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ J Pers Med, 2022, 12(2)258] PubMed: 35207746

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.